Renal Function and All-Cause Mortality Risk Among Cancer Patients

被引:42
|
作者
Yang, Yan [1 ]
Li, Hui-yan [1 ]
Zhou, Qian [1 ]
Peng, Zhen-wei [2 ]
An, Xin [3 ]
Li, Wei [1 ]
Xiong, Li-ping [1 ]
Yu, Xue-qing [1 ]
Jiang, Wen-qi [3 ]
Mao, Hai-ping [1 ]
机构
[1] Sun Yat Sen Univ, Key Lab Nephrol, Minist Hlth China,Dept Nephrol, Guangdong Prov Key Lab Nephrol,Affiliated Hosp 1, 58 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Oncol, 58 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Ctr Canc, Dept Oncol, 651 Dongfeng Rd, Guangzhou 510080, Guangdong, Peoples R China
关键词
CHRONIC KIDNEY-DISEASE; COLORECTAL-CANCER; SURGICAL RESECTION; LUNG-CANCER; COMORBIDITY; INSUFFICIENCY; THERAPY; IMPACT; AGE; IMPAIRMENT;
D O I
10.1097/MD.0000000000003728
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Renal dysfunction predicts all-cause mortality in general population. However, the prevalence of renal insufficiency and its relationship with mortality in cancer patients are unclear. We retrospectively studied 9465 patients with newly diagnosed cancer from January 2010 to December 2010. Renal insufficiency was defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m(2) using the Chronic Kidney Disease Epidemiology Collaboration equation. The hazard ratio (HR) of all-cause mortality associated with baseline eGFR was assessed by Cox regression. Three thousand sixty-nine patients (32.4%) exhibited eGFR < 90 mL/min/1.73 m(2) and 3% had abnormal serum creatinine levels at the time of diagnosis. Over a median follow-up of 40.5 months, 2705 patients (28.6%) died. Compared with the reference group (eGFR >= 60 mL/min/1.73 m 2), an elevated all-cause mortality was observed among patients with eGFR< 60 mL/min/1.73 m(2) stratified by cancer stage in the entire cohort, the corresponding hazard ratios were 1.87 (95% CI, 1.41-2.47) and 1.28 (95% CI, 1.01-1.62) for stage I to III and stage IV, respectively. However, this relationship was not observed after multivariate adjustment. Subgroup analysis found that eGFR< 60 mL/min/1.73m 2 independently predicted death among patients with hematologic (adjusted HR 2.93, 95% CI [1.36-6.31]) and gynecological cancer (adjusted HR 2.82, 95% CI [1.19-6.70]), but not in those with other cancer. Five hundred fifty-seven patients (6%) had proteinuria. When controlled for potential confounding factors, proteinuria was a risk factor for all-cause mortality among patients in the entire cohort, regardless of cancer stage and eGFR values. When patients were categorized by specific cancer type, the risk of all-cause death was only significant in patients with digestive system cancer (adjusted HR, 1.85 [1.48-2.32]). The prevalence of renal dysfunction was common in patients with newly diagnosed cancer. Patients with eGFR < 60 mL/min/1.73 m(2) or proteinuria were associated with increased risk for all-cause mortality, this relation depended on cancer site.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] All-cause mortality among breast cancer patients in a screening trial: support for breast cancer mortality as an end point
    Tabar, L
    Duffy, SW
    Yen, MF
    Warwick, J
    Vitak, B
    Chen, HH
    Smith, RA
    [J]. JOURNAL OF MEDICAL SCREENING, 2002, 9 (04) : 159 - 162
  • [32] All-Cause and Cancer-Specific Mortality Among Patients With Cancer Infected or Not Infected With HIV Reply
    Coghill, Anna E.
    Shiels, Meredith S.
    Suneja, Gita
    Engels, Eric A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04) : 390 - U174
  • [33] Using alternatives to the car and risk of all-cause, cardiovascular and cancer mortality
    Panter, Jenna
    Mytton, Oliver
    Sharp, Stephen
    Brage, Soren
    Cummins, Steven
    Laverty, Anthony A.
    Wijndaele, Katrien
    Ogilvie, David
    [J]. HEART, 2018, 104 (21) : 1749 - 1755
  • [34] Sitting Time and All-Cause Mortality Risk
    Peterson, Mark D.
    Sarma, Aruna V.
    Gordon, Paul M.
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2012, 172 (16) : 1270 - 1272
  • [35] Healthy behaviours and risk of all-cause mortality
    Lahti, Jouni
    Mauramo, E.
    Lahelma, E.
    Lallukka, T.
    Pietilainen, O.
    Salmela, J.
    Salonsalmi, A.
    Rahkonen, O.
    [J]. EUROPEAN JOURNAL OF PUBLIC HEALTH, 2019, 29
  • [36] Blockers Are Associated With Reduced All-Cause Mortality Among HFpEF Patients
    Ibrahim, Joseph
    Fabrizio, Carly
    Sezer, Ahmet
    Thoma, Floyd
    Simon, Marc
    Mulukutla, Suresh
    Hickey, Gavin W.
    [J]. JOURNAL OF CARDIAC FAILURE, 2022, 28 (05) : S51 - S51
  • [37] Association of anaemia and all-cause mortality in patients with ischaemic heart failure varies by renal function status
    Cai, Anping
    Wu, Zejia
    Xu, Lan
    Xia, Shuang
    He, Xuyu
    Zhang, Ying
    Chen, Jiyan
    Zhou, Yingling
    Li, Liwen
    [J]. ESC HEART FAILURE, 2021, 8 (03): : 2270 - 2281
  • [38] Trends in all-cause mortality among patients with chronic myeloid leukemia
    Brunner, Andrew M.
    Campigotto, Federico
    Sadrzadeh, Hossein
    Drapkin, Benjamin J.
    Chen, Yi-Bin
    Neuberg, Donna S.
    Fathi, Amir T.
    [J]. CANCER, 2013, 119 (14) : 2620 - 2629
  • [39] Supersilent myocardial ischemia and risk of all-cause mortality in elderly patients
    Bouzas Mosquera, A.
    Peteiro, J.
    Broullon Molanes, F. J.
    Alvarez Garcia, N.
    Garcia Guimaraes, M. M.
    Martinez Ruiz, D.
    Yanez Wonenburger, J. C.
    Bouzas Zubeldia, B.
    Fabregas Casal, R.
    Castro Beiras, A.
    [J]. EUROPEAN HEART JOURNAL, 2013, 34 : 411 - 411
  • [40] Risk of all-cause and cardiovascular mortality in patients with chronic liver disease
    Targher, Giovanni
    Zoppini, Giacomo
    Day, Christopher P.
    [J]. GUT, 2011, 60 (11) : 1602 - 1603